Revvity (NYSE:RVTY – Get Free Report) issued its earnings results on Monday. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.10, RTT News reports. The company had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. Revvity had a return on equity of 7.35% and a net margin of 6.26%. The firm’s quarterly revenue was down 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.21 EPS. Revvity updated its FY 2024 guidance to 4.700-4.800 EPS and its FY24 guidance to $4.70-4.80 EPS.
Revvity Trading Up 1.3 %
Shares of RVTY opened at $127.24 on Wednesday. Revvity has a twelve month low of $79.50 and a twelve month high of $127.88. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $15.70 billion, a P/E ratio of 105.16, a PEG ratio of 3.27 and a beta of 1.05. The firm’s 50-day moving average is $109.37 and its two-hundred day moving average is $106.68.
Revvity Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.22%. The ex-dividend date is Friday, October 18th. Revvity’s dividend payout ratio (DPR) is 23.14%.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on RVTY
Insider Transactions at Revvity
In related news, insider Joel S. Goldberg sold 4,000 shares of the stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $110.46, for a total value of $441,840.00. Following the sale, the insider now directly owns 36,900 shares of the company’s stock, valued at approximately $4,075,974. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.60% of the company’s stock.
About Revvity
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
See Also
- Five stocks we like better than Revvity
- The 3 Best Fintech Stocks to Buy Now
- 5 Aggressive Growth Stocks for Long-Term Investors
- Canadian Penny Stocks: Can They Make You Rich?
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.